Tagged with PR

Canada In total there were 27 new active substances (NASs) approved in Canada in 2018, 18 prescription pharmaceutical drugs and 9 biologics. In terms of companies that saw particular success last year, Merck (MSD outside of the US and Canada) had three prescription drugs approved, as did Swiss-headquartered Vifor Pharma. Global…

Spain Dr Juan Abarca Cidón, president of HM Hospitales, one of Spain’s leading private health groups, gives insight into the private health sector of the country, its relation to the public system, and the opportunities that exist to interact. Dr Abarca goes on to discuss the R&D capabilities of the group…

Spain Stephen Matlin, CEO of Life Length, highlights the evolution of the company over recent years, especially the establishment of their own laboratories which have allowed them to conduct clinical studies for diagnostic and prognostic tests in cancer. Furthermore, he points out the need to better value preventative medicine and how…

Spain Carlos Rus Palacios, general secretary of the Alliance of Spanish Private Healthcare (ASPE), the association of private hospitals and private health centers in Spain, delivers his message on the importance of the private sector within Spain’s healthcare system and the shift in mindset that must be realized by health stakeholders…

Spain Yann Gaslain, CEO of Procare Health, a local player dedicated to innovative natural women’s health products, outlines his strategy to set up the company since 2012 and gives an overview of his company’s star product, Papilocare. Furthermore, he points out the company’s internationalisation and R&D strategy and highlights the importance…

Turkey Gamze Çıtıroğlu, Murat Çıtıroğlu and Pınar Çakır of Ekin Kimya discuss the progress of the Turkish pharma industry moving towards biotechnology. Moreover, they give insights into Ekin Kimya’s partnership strategy for pharmaceutical production, highlighting the importance of quality and customer-centricity.   Turkey’s pharma sector is growing rapidly and it comes…

France Nicolas Bardonnet of Promega France discusses the standout growth of the company on the occasion of its 40th anniversary, collaboration with France’s biotech clusters and the growth drivers of the future.   In France, we start to see hospitals coming to us, but also clinical diagnostic laboratories because for a…

Opinion Aditya Bhattacharji manages Eurasia Group‘s healthcare analysis. In this article, he gives his predictions for the political landscape in healthcare for 2019.  The challenges for firms are painfully apparent—there is bipartisan support in the US to lower drug prices, a pervasive sense that traditional advocacy methods are failing in today’s political climate,…

Opinion Axel Schumacher, co-founder and chief scientific officer of Shivom, a data-driven next generation precision-medicine company in the blockchain space, calls for Pharma to leverage big-data on a global level to ensure all patients have a therapy option.    The key to success for pharma players is to sponsor the accumulation of…

Spain Gijs Jochems, general manager of Promega Biotech Iberica, a leading molecular biology solutions provider, speaks about the company’s business transformation to collaborate with diverse areas of the private sector. Jochems goes on to give his insights on the state of Spanish innovation and highlights how Promega uses its commitment to…

Malaysia Chuwn Leong Ch’ng, CEO of Thunder Print, presents his company’s strategic role within the Malaysian healthcare industry to provide a high-quality packaging services for all type of health products, from medicines to health supplements.   Today, we are one of the few printers in Malaysia that offer a complete range…

Malaysia Tan Sri Dato’ Ariffin Yusuf, founder and managing director of Primabumi, explains how he came to build Primabumi in 1975 and how he managed to position the company as a strategic partner for healthcare companies interested in winning public tenders. With his long business experience with the government, he also…